Beacon Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Beacon Therapeutics sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials 1 currently recruiting 6 completed early-phase tilt top decile by trial count

Beacon Therapeutics: 12 sponsored US clinical trials, 1 recruiting.

Beacon Therapeutics sponsors 12 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 6 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is X-Linked Retinitis Pigmentosa, with 3 trials.

Top-decile sponsor footprint

Beacon Therapeutics ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

12 total, page 1 of 1

RECRUITING Phase 2

A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis Pigmentosa

NCT07174726
ACTIVE NOT RECRUITING Phase 2

A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

NCT04850118
ACTIVE NOT RECRUITING Phase 2

A Study Comparing Two Doses of AGTC-501 in Male Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations (SKYLINE)

NCT06333249
ACTIVE NOT RECRUITING Phase 1

Safety and Efficacy of rAAV2tYF-GRK1-RPGR in Subjects With X-linked Retinitis Pigmentosa Caused by RPGR Mutations

NCT03316560
ACTIVE NOT RECRUITING Phase 1

Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)

NCT02935517
ACTIVE NOT RECRUITING Phase 1

Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)

NCT02599922
COMPLETED

Clinical Evaluation of Patients With X-linked Retinitis Pigmentosa (XLRP)

NCT03314207
COMPLETED Phase 1

Safety and Efficacy of rAAV-hRS1 in Patients With X-linked Retinoschisis (XLRS)

NCT02416622
COMPLETED

Clinical and Genetic Characterization of Individuals With Achromatopsia

NCT01846052
COMPLETED

Clinical Evaluation of Patients With X-linked Retinoschisis

NCT02331173
COMPLETED Phase 2

Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency

NCT01054339
COMPLETED Phase 1

Phase 1/2 Safety and Efficacy Study of AAV-RPE65 Vector to Treat Leber Congenital Amaurosis

NCT00749957

Phase Distribution

PhaseTrial count
Phase 1 5
Phase 2 4

Therapeutic Areas

X-Linked Retinitis Pigmentosa 3
Achromatopsia 3
X-Linked Retinitis Pigmentosa (XLRP) 1
X-linked Retinoschisis 1
Alpha-1 Antitrypsin Deficiency 1

What is open in the Beacon Therapeutics pipeline

1 recruiting of 12 indexed (8% open); 6 completed (50%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: X-Linked Retinitis Pigmentosa (3 trials), 4 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Beacon Therapeutics: open-pipeline peers nationwide

Peers matched on 12 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

Beacon Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 10152025 0%5%10%15%20% Total trials Recruiting share Beacon TherapeuticsAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.AngiodynamicsAcrotech BiopharmaAtlanta VA Medical CenterBoston VA Research InstituteCentrexion Therapeutics
Beacon Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Beacon Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Beacon Therapeutics page

12 registered trials is a research-attention snapshot, not an endorsement of Beacon Therapeutics or any single study.

  • 1 of Beacon Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • X-Linked Retinitis Pigmentosa is the condition Beacon Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See X-Linked Retinitis Pigmentosa trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Beacon Therapeutics pipeline card: 12 registered trials from official public datasets.Report a data error.